Cargando…

Efficacy and safety of Ginkgo biloba standardized extract in the treatment of vascular cognitive impairment: a randomized, double-blind, placebo-controlled clinical trial

OBJECTIVES: The aim of this randomized, double-blind, placebo-controlled trial was to determine the efficacy and safety of Ginkgo biloba extract in patients diagnosed with vascular cognitive impairment (VCI). METHODS: A total of 90 patients (aged 67.1±8.0 years; 59 women) were randomly allocated (1:...

Descripción completa

Detalles Bibliográficos
Autores principales: Demarin, Vida, Bašić Kes, Vanja, Trkanjec, Zlatko, Budišić, Mislav, Bošnjak Pašić, Marija, Črnac, Petra, Budinčević, Hrvoje
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5317341/
https://www.ncbi.nlm.nih.gov/pubmed/28243101
http://dx.doi.org/10.2147/NDT.S120790
_version_ 1782508986821509120
author Demarin, Vida
Bašić Kes, Vanja
Trkanjec, Zlatko
Budišić, Mislav
Bošnjak Pašić, Marija
Črnac, Petra
Budinčević, Hrvoje
author_facet Demarin, Vida
Bašić Kes, Vanja
Trkanjec, Zlatko
Budišić, Mislav
Bošnjak Pašić, Marija
Črnac, Petra
Budinčević, Hrvoje
author_sort Demarin, Vida
collection PubMed
description OBJECTIVES: The aim of this randomized, double-blind, placebo-controlled trial was to determine the efficacy and safety of Ginkgo biloba extract in patients diagnosed with vascular cognitive impairment (VCI). METHODS: A total of 90 patients (aged 67.1±8.0 years; 59 women) were randomly allocated (1:1:1) to receive G. biloba 120 mg, G. biloba 60 mg, or placebo during a 6-month period. Assessment was made for efficacy indicators, including neuropsychological tests scores (Sandoz Clinical Assessment Geriatric Scale, Folstein Mini-Mental State Examination, Mattis Dementia Rating Scale, and Clinical Global Impression) and transcranial Doppler ultrasound findings. Safety indicators included laboratory findings, reported adverse reactions, and clinical examination. RESULTS: At the end of 6-month study period, G. biloba 120 and 60 mg showed a statistically significant positive effect in comparison with placebo only on the Clinical Global Impression score (2.6±0.8 vs 3.1±0.7 vs 2.8±0.7, respectively; P=0.038). The Clinical Global Impression score showed a significant deterioration from the baseline values in the placebo group (−0.3±0.5; P=0.021) as opposed to G. biloba groups. No significant differences were found in the transcranial Doppler ultrasound findings. Adverse reactions were significantly more common and serious in the placebo group (16 subjects) than in either of the two G. biloba extract groups (eight and nine subjects, respectively), whereas laboratory findings and clinical examinations revealed no differences between the groups receiving G. biloba extract and placebo. CONCLUSION: According to our results, G. biloba seemed to slow down the cognitive deterioration in patients with VCI, but the effect was shown in only one of the four neuropsychological tests administered. However, because of this mild effect in combination with a few adverse reactions, we cannot say that it is ineffective or unsafe either. Further studies are still needed to provide unambiguous evidence on the efficacy and safety of G. biloba extract.
format Online
Article
Text
id pubmed-5317341
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-53173412017-02-27 Efficacy and safety of Ginkgo biloba standardized extract in the treatment of vascular cognitive impairment: a randomized, double-blind, placebo-controlled clinical trial Demarin, Vida Bašić Kes, Vanja Trkanjec, Zlatko Budišić, Mislav Bošnjak Pašić, Marija Črnac, Petra Budinčević, Hrvoje Neuropsychiatr Dis Treat Original Research OBJECTIVES: The aim of this randomized, double-blind, placebo-controlled trial was to determine the efficacy and safety of Ginkgo biloba extract in patients diagnosed with vascular cognitive impairment (VCI). METHODS: A total of 90 patients (aged 67.1±8.0 years; 59 women) were randomly allocated (1:1:1) to receive G. biloba 120 mg, G. biloba 60 mg, or placebo during a 6-month period. Assessment was made for efficacy indicators, including neuropsychological tests scores (Sandoz Clinical Assessment Geriatric Scale, Folstein Mini-Mental State Examination, Mattis Dementia Rating Scale, and Clinical Global Impression) and transcranial Doppler ultrasound findings. Safety indicators included laboratory findings, reported adverse reactions, and clinical examination. RESULTS: At the end of 6-month study period, G. biloba 120 and 60 mg showed a statistically significant positive effect in comparison with placebo only on the Clinical Global Impression score (2.6±0.8 vs 3.1±0.7 vs 2.8±0.7, respectively; P=0.038). The Clinical Global Impression score showed a significant deterioration from the baseline values in the placebo group (−0.3±0.5; P=0.021) as opposed to G. biloba groups. No significant differences were found in the transcranial Doppler ultrasound findings. Adverse reactions were significantly more common and serious in the placebo group (16 subjects) than in either of the two G. biloba extract groups (eight and nine subjects, respectively), whereas laboratory findings and clinical examinations revealed no differences between the groups receiving G. biloba extract and placebo. CONCLUSION: According to our results, G. biloba seemed to slow down the cognitive deterioration in patients with VCI, but the effect was shown in only one of the four neuropsychological tests administered. However, because of this mild effect in combination with a few adverse reactions, we cannot say that it is ineffective or unsafe either. Further studies are still needed to provide unambiguous evidence on the efficacy and safety of G. biloba extract. Dove Medical Press 2017-02-16 /pmc/articles/PMC5317341/ /pubmed/28243101 http://dx.doi.org/10.2147/NDT.S120790 Text en © 2017 Demarin et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Demarin, Vida
Bašić Kes, Vanja
Trkanjec, Zlatko
Budišić, Mislav
Bošnjak Pašić, Marija
Črnac, Petra
Budinčević, Hrvoje
Efficacy and safety of Ginkgo biloba standardized extract in the treatment of vascular cognitive impairment: a randomized, double-blind, placebo-controlled clinical trial
title Efficacy and safety of Ginkgo biloba standardized extract in the treatment of vascular cognitive impairment: a randomized, double-blind, placebo-controlled clinical trial
title_full Efficacy and safety of Ginkgo biloba standardized extract in the treatment of vascular cognitive impairment: a randomized, double-blind, placebo-controlled clinical trial
title_fullStr Efficacy and safety of Ginkgo biloba standardized extract in the treatment of vascular cognitive impairment: a randomized, double-blind, placebo-controlled clinical trial
title_full_unstemmed Efficacy and safety of Ginkgo biloba standardized extract in the treatment of vascular cognitive impairment: a randomized, double-blind, placebo-controlled clinical trial
title_short Efficacy and safety of Ginkgo biloba standardized extract in the treatment of vascular cognitive impairment: a randomized, double-blind, placebo-controlled clinical trial
title_sort efficacy and safety of ginkgo biloba standardized extract in the treatment of vascular cognitive impairment: a randomized, double-blind, placebo-controlled clinical trial
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5317341/
https://www.ncbi.nlm.nih.gov/pubmed/28243101
http://dx.doi.org/10.2147/NDT.S120790
work_keys_str_mv AT demarinvida efficacyandsafetyofginkgobilobastandardizedextractinthetreatmentofvascularcognitiveimpairmentarandomizeddoubleblindplacebocontrolledclinicaltrial
AT basickesvanja efficacyandsafetyofginkgobilobastandardizedextractinthetreatmentofvascularcognitiveimpairmentarandomizeddoubleblindplacebocontrolledclinicaltrial
AT trkanjeczlatko efficacyandsafetyofginkgobilobastandardizedextractinthetreatmentofvascularcognitiveimpairmentarandomizeddoubleblindplacebocontrolledclinicaltrial
AT budisicmislav efficacyandsafetyofginkgobilobastandardizedextractinthetreatmentofvascularcognitiveimpairmentarandomizeddoubleblindplacebocontrolledclinicaltrial
AT bosnjakpasicmarija efficacyandsafetyofginkgobilobastandardizedextractinthetreatmentofvascularcognitiveimpairmentarandomizeddoubleblindplacebocontrolledclinicaltrial
AT crnacpetra efficacyandsafetyofginkgobilobastandardizedextractinthetreatmentofvascularcognitiveimpairmentarandomizeddoubleblindplacebocontrolledclinicaltrial
AT budincevichrvoje efficacyandsafetyofginkgobilobastandardizedextractinthetreatmentofvascularcognitiveimpairmentarandomizeddoubleblindplacebocontrolledclinicaltrial